EXEL vs HALO
Exelixis, Inc. (EXEL) and Halozyme Therapeutics, Inc. (HALO) are both filed with the SEC under Biological Products, (No Diagnostic Substances). EXEL is 1.1× HALO's size by market cap ($13.7B against $12.1B); HALO trades at the higher fiscal-year P/E (41.8× against 31.4×); EXEL reports the higher net margin (33.7% against 22.7%); HALO grew sales faster over three years (+28.4% against +12.9%); and over the past year HALO returned +44.7% against EXEL's +43.7%.
| EXEL | HALO | |
|---|---|---|
| Last close | $54.45 | $105.35 |
| Market cap | $13.7B | $12.1B |
| P/E (FY) | 31.4× | 41.8× |
| P/S | 5.9× | 8.7× |
| EV/EBITDA | — | 29.4× |
| Operating margin | 37.6% | 33.6% |
| Net margin | 33.7% | 22.7% |
| Return on equity | 35.5% | 153.6% |
| Sales growth (3y) | +12.9% | +28.4% |
| EPS growth (3y) | +70.6% | +21.1% |
| 1-year return | +43.7% | +44.7% |
Screener snapshot — prices as of 2026-08-28. Each side's last close is the most recent session the snapshot holds for that company, which can be an earlier one, and its 1-year return is measured to that close. Market caps struck on 2026-08-27. Last close, market cap and the 1-year return are price figures; every other row is computed over the company's latest filed fiscal year, and the two differ: EXEL FY2026 (ended 2026-01-02); HALO FY2025 (ended 2025-12-31). A return on equity past ±100% — HALO at 153.6% — divides earnings by an average filed equity base smaller in magnitude than the earnings themselves; the two columns are not on one scale. — not published for this company. A ratio goes unpublished for more than one reason: a component the calculation needs is not on file, the filing does not tag the line it is read from, or the calculation is not defined on the filed basis — EV/EBITDA is not printed on non-positive EBITDA, and return on equity is not computed on a zero or negative equity base.
Who holds them, and who has traded them
| EXEL | HALO | |
|---|---|---|
| Institutional holders (13F) | 693 | 633 |
| Insider buyers − sellers (180d) | -5 | -4 |
| Congressional trades disclosed (180d) | 0 | 1 |
| Executive-branch officials on file — trades disclosed (180d) | 0 | 0 |
Counts only. The congressional figures count transactions dated in the trailing 180 days and disclosed in STOCK Act periodic transaction reports; amounts are filed as ranges and are never summed. The executive-branch figures count the same window of transactions, and they are scoped to one roster. The officials OGE posts for direct download. Insider buyers − sellers counts distinct people filing open-market Form 4 purchases minus distinct people filing open-market sales over the trailing 180 days, capped at ±5.
EXEL vs HALO: common questions
- Is EXEL bigger than HALO?
- EXEL carries the larger market cap — $13.7B against $12.1B, both struck on 2026-08-27.
- Which trades at a higher P/E, EXEL or HALO?
- HALO, at a fiscal-year 41.8× against 31.4× for EXEL. Both are price ÷ latest full-year diluted earnings per share, not a trailing-twelve-month P/E.
- How have EXEL and HALO performed over the past year?
- HALO returned +44.7% and EXEL +43.7%, measured on the trailing calendar year to the last close.
- How many institutions hold EXEL and HALO?
- 693 13F filers report a position in EXEL and 633 in HALO, on the latest quarter in the panel.
- Are EXEL and HALO in the same industry?
- Both are filed with the SEC under Biological Products, (No Diagnostic Substances), which is the classification this pairing is built on.
EXEL overview → · HALO overview → · EXEL institutional ownership → · HALO institutional ownership → · Congress and HALO →
More in Biological Products, (No Diagnostic Substances): AMGN vs BIIB · AMGN vs EXEL · AMGN vs GILD · AMGN vs HALO
Stock comparisons lists every pair this site publishes.
Source: SPZCO — https://spzco.com/vs/exel-vs-halo